April 25th 2024
In LEVEL-UP, upadacitinib demonstrated superiority over dupilumab in achieving EASI-90 and little to no itch at week 16.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Diving into Atopic Dermatitis and its Rapidly Expanding Pipeline
January 15th 2022In this video interview, Peter A. Lio, MD, FAAD, expands on his Winter Clinical Dermatology 2022 presentation, "What's Hot and New in Pediatric Dermatology?" He talks the pipeline, black box warnings, and more on atopic dermatitis treatments.
FDA approves Tralokinumab-Idrm for AD
December 28th 2021Leo Pharma has announced the FDA approval of tralokinumab-Idrm (Adbry; Leo Pharma) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older. Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at George Washington University School of Medicine and Health Sciences, and tralokinumab clinical trial investigator gives his comments on this approval.